Healthcare Providers and Services
Company Overview of Enzo Clinical Labs, Inc.
Enzo Clinical Labs, Inc. operates clinical reference laboratories in the United States. It offers various assays in the areas of chemistry, fertility and hormone studies, pregnancy, hematology, and coagulation. The company also provides electronic report delivery services for physicians. In addition, it offers phlebotomy services for patients needing blood tests through its network of patient service centers; diagnostic test that assists in risk assessment and early detection of lung cancer; and ColonSentry, a blood test to assess an individual's current risk for colorectal cancer. Enzo Clinical Labs, Inc. is based in Farmingdale, New York. The company has patient service centers in Manhatta...
60 Executive Boulevard
Farmingdale, NY 11735
Key Executives for Enzo Clinical Labs, Inc.
Chairman of the Board and Chief Executive Officer
President of Enzo Biochem Inc
Scientific Director and Associate Medical Director
Compensation as of Fiscal Year 2016.
Enzo Clinical Labs, Inc. Key Developments
Enzo Clinical Labs, Inc. Reports Unaudited Earnings Results for the First Quarter Ended October 31, 2015
Dec 7 15
Enzo Clinical Labs, Inc. reported unaudited earnings results for the first quarter ended October 31, 2015. For the quarter, the company reported revenues of $17.1 million, an increase of $1.3 million or 8%, over prior year of $15.9 million, due to the continued focus on its menu of high margin molecular-based assays. Operating profit advanced to $0.8 million, from just above break-even last year.
Enzo Clinical Labs Announces Unaudited Earnings Results for the Third Quarter Ended April 30, 2015
Jun 9 15
Enzo Clinical Labs announced unaudited earnings results for the third quarter ended April 30, 2015. For the quarter, the company revenues grew to $15.7 million, an 8% increase over the prior year period. Operating income was $0.3 million, a $3.6 million turnaround from a year ago.
Enzo Clinical Labs, Inc. Reports Unaudited Earnings Results for the First Quarter Ended October 31, 2014
Dec 9 14
Enzo Clinical Labs, Inc. reported unaudited earnings results for the first quarter ended October 31, 2014. For the quarter, the company reported that its results benefited from several factors, including greater emphasis and use of molecular diagnostic testing and increased operating efficiencies from streamlining efforts and recently implemented process and operational enhancements. Revenues increased 6%, to a record $15.8 million. Operating income was essentially breakeven, a $900,000 improvement compared to a year ago operating loss of approximately $0.9 million, and EBITDA was a positive $0.4 million, compared to last year’s negative EBITDA of $0.5 million.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|